Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jihad Inshasi

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Neurology and Therapy|April 17, 2020
Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing-Remitting Multiple Sclerosis Patients? A Narrative ReviewIsa Ahmed AlSharoqi, Mohamed Aljumah, Saeed Bohlega, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|June 6, 2017
Decompressive Hemicraniectomy for Malignant Middle Cerebral Artery Stroke: South Asian ExperienceSaadat Kamran, Naveed Akhtar, Abdul Salam, et al.
CNS Drugs|June 24, 2021
Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009-2018Nahid Moradi, Sifat Sharmin, Charles Malpas, et al.
Neurology and Therapy|May 17, 2025
Role of Immune Reconstitution Therapy with Cladribine Tablets in the Management of Relapsing Multiple Sclerosis in Older PatientsRaed Alroughani, Jihad Inshasi, Samar Farouk, et al.
Multiple Sclerosis International|January 13, 2017
Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus RisksRaed Alroughani, Ayse Altintas, Mohammed Al Jumah, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 30, 2022
External validation of a clinical prediction model in multiple sclerosisNahid Moradi, Sifat Sharmin, Charles B Malpas, et al.
Multiple Sclerosis and Related Disorders|August 9, 2024
Disease-modifying therapies, outcomes, risk factors and severity of COVID-19 in multiple sclerosis: A MENACTRIMS registry based studyMaya Zeineddine, Amal Al-Hajje, Pascale Salameh, et al.
Neurology and Therapy|August 3, 2024
Practical Recommendations from the Gulf Region on the Therapeutic Use of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis: Impact of the Latest Real-World Evidence on Clinical PracticeBassem Yamout, Raed Alroughani, Jihad Inshasi, et al.
CNS Drugs|January 27, 2026
Consensus Recommendations for the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD): The MENACTRIMS GuidelinesBassem Yamout, Riadh Gouider, Raed Al-Roughani, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 26, 2024
Safety and effectiveness of disease-modifying therapies after switching from natalizumabMaya Zeineddine, Raed Al-Roughani, Samar Farouk Ahmed, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Neurology and Therapy|April 17, 2020
Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing-Remitting Multiple Sclerosis Patients? A Narrative ReviewIsa Ahmed AlSharoqi, Mohamed Aljumah, Saeed Bohlega, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|June 6, 2017
Decompressive Hemicraniectomy for Malignant Middle Cerebral Artery Stroke: South Asian ExperienceSaadat Kamran, Naveed Akhtar, Abdul Salam, et al.
CNS Drugs|June 24, 2021
Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009-2018Nahid Moradi, Sifat Sharmin, Charles Malpas, et al.
Neurology and Therapy|May 17, 2025
Role of Immune Reconstitution Therapy with Cladribine Tablets in the Management of Relapsing Multiple Sclerosis in Older PatientsRaed Alroughani, Jihad Inshasi, Samar Farouk, et al.
Multiple Sclerosis International|January 13, 2017
Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus RisksRaed Alroughani, Ayse Altintas, Mohammed Al Jumah, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 30, 2022
External validation of a clinical prediction model in multiple sclerosisNahid Moradi, Sifat Sharmin, Charles B Malpas, et al.
Multiple Sclerosis and Related Disorders|August 9, 2024
Disease-modifying therapies, outcomes, risk factors and severity of COVID-19 in multiple sclerosis: A MENACTRIMS registry based studyMaya Zeineddine, Amal Al-Hajje, Pascale Salameh, et al.
Neurology and Therapy|August 3, 2024
Practical Recommendations from the Gulf Region on the Therapeutic Use of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis: Impact of the Latest Real-World Evidence on Clinical PracticeBassem Yamout, Raed Alroughani, Jihad Inshasi, et al.
CNS Drugs|January 27, 2026
Consensus Recommendations for the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD): The MENACTRIMS GuidelinesBassem Yamout, Riadh Gouider, Raed Al-Roughani, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 26, 2024
Safety and effectiveness of disease-modifying therapies after switching from natalizumabMaya Zeineddine, Raed Al-Roughani, Samar Farouk Ahmed, et al.
Pageof 5